Archives: Agenda

PANEL DISCUSSION: The Rise of Chinese Biotech: a competitive challenge for U.S. companies and investors
专题讨论 中国生物科技崛起：美国企业与投资者的竞争挑战

  • The Rise of China’s Biotech Industry: The Chinese government’s “Made in China 2025” strategy and its impact on biotech innovation
  • The role of China’s National Medical Products Administration (NMPA) in accelerating drug approvals
  • The Role of Venture Capital in China’s Biotech Boom; How Chinese VCs and state-backed funds are fueling biotech startups and the differences between U.S. and Chinese biotech funding models
  • Competitive Pressure on U.S. Biotech Firms
  • Regulatory & Geopolitical Challenges: The impact of U.S.-China trade tensions and export controls on biotech collaboration

Moderator:

Claire Qin, Chief Strategy Officer, Intelligen AI; BioPharma Investor

 

中国生物科技产业迅猛发展，在药物研发、临床试验及全球市场拓展方面对美国生物科技企业构成日益激烈的竞争。凭借政府强力支持、资本优势及创新疗法管线的持续扩充，在风险投资（VC）加持下的中国生物科技企业正在重塑行业格局。本环节将深入分析竞争态势、美国企业面临的挑战以及全球生物科技创新的未来走向。

  • 中国生物科技产业崛起：”中国制造2025″战略对生物科技创新的推动效应
  • 监管加速作用：中国国家药品监督管理局（NMPA）在新药审批中的角色演进
  • 资本驱动力量：中美国际资本运作模式差异——中国风险投资与政府基金如何赋能生物科技初创企业
  • 美国企业的竞争压力：核心技术与市场份额的双重挑战
  • 监管与地缘政治因素：中美贸易摩擦及出口管制对生物科技合作的影响

主持嘉宾:
秦祯，首席战略官，Intelligen AI

ROUNDTABLE SESSIONS
嘉宾主持圆桌讨论会

During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

ROUNDTABLE 1

What key aspects of inspection readiness should be considered right now?

Hosted By Claire Qin, Chief Strategy Officer, Intelligen AI; BioPharma Investor

ROUNDTABLE 2

Getting the best out of your sponsor – CRO partnership

Hosted by Megan Qin, Head of Medical Device Clinical Excellence Working Group, CMAC

ROUNDTABLE 3

Ensuring clinical quality assurance in supply chain management

Hosted By Daniel Gao, President, ISPE Supply Chain Committee

互动式圆桌会议为您提供与同行深入交流的独特机会，共同探讨行业关键挑战的解决方案并分享最佳实践。每场讨论由行业专家主持，聚焦单一议题，通过高互动形式拓展人脉网络，汲取他人经验智慧。
（每场圆桌讨论时长30分钟，参会者可轮换参与）

圆桌议题1：中国药企出海的机遇与挑战
主持嘉宾：秦祯，首席战略官，Intelligen AI

圆桌议题2：如何构建最优申办方-CRO合作伙伴关系
主持嘉宾：秦飞，卓越临床联盟医疗器械工作组负责人，CMAC

圆桌议题3：临床试验供应链质量管理保障机制
主持嘉宾：高晓伟，主席，ISPE供应链分会

Patient Centricity in Clinical Trials: A New Era in China
以患者为中心的临床试验：中国新时代

As China’s clinical trial ecosystem evolves, there is a growing emphasis on patient-centric approaches to improve recruitment, retention, and overall trial outcomes. This session will explore strategies to enhance patient engagement, leverage digital health solutions, and address cultural and regulatory considerations for patient-centric clinical trials in China.

  • Understanding the Shift Toward Patient- Centric Trials in China.
  • Enhancing Patient Recruitment and Retention
  • Digital Health and Remote Monitoring in Patient- Centric Trials.
  • Regulatory and Ethical

随着中国临床试验生态系统的演进，聚焦患者需求的 模式正显著提升受试者招募、留存及整体试验质量。 本环节将探讨如何通过数字化健康解决方案增强患者 参与度，并解析中国患者中心式试验中的文化适应性 与监管要求

  • 去中心化临床试验 DCT 的发展历程
  • 国内外相关法规对 DCT 的指导要求
  • DCT 技术在临床研究中的具体应用和实践
  • 关于 DCT 发展趋势的展望和应对。